Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Robert W Baird Global Healthcare Conference (Virtual) Transcript

Sep 09, 2020 / 03:25PM GMT
Michael Eric Ulz
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

All right. Great, and good morning. And thanks to everyone for joining us at the Baird 2020 Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here at Baird, and it's my pleasure to introduce the team from BioMarin, including J.J. Bienaimé, Chairman and CEO. We also have Brian Mueller, CFO; and Hank Fuchs, President of Worldwide Research and Development.

So just a quick reminder, the format for today is a fireside chat. So if you have a question, please feel free to submit one through the webcast portal, which is anonymous, and I'll be sure to ask a question on your behalf. But before we jump into the Q&A here, I'll just turn it over to J.J. to make some introductory comments. J.J.?

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Yes. Thank you, Mike. We appreciate the opportunity to speak with you today. It has been a very active few weeks for us,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot